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Quantitative proteomicsChronic obstructive pulmonary disease (COPD) is one of the most prevalent lung diseases. Cigarette smoking is
the main risk factor for COPD. In this parallel-group clinical study we investigated to what extent the transitions
in a chronic-exposure-to-diseasemodel are reﬂected in the proteome and cellular transcriptome of induced spu-
tum samples. We selected 60 age- and gender-matched individuals for each of the four study groups: current
asymptomatic smokers, smokers with early stage COPD, former smokers, and never smokers. The cell-free spu-
tum supernatant was analyzed by quantitative proteomics and the cellular mRNA fraction by gene expression
proﬁling. The sputum proteome of current smokers clearly reﬂected the common physiological responses to
smoke exposure, including alterations in mucin/trefoil proteins and a prominent xenobiotic/oxidative stress re-
sponse. The latter response also was observed in the transcriptome, which additionally demonstrated an
immune-cell polarization change. The former smoker group showednearly complete attenuation of these biolog-
ical effects. Thirteen differentially abundant proteins between the COPD and the asymptomatic smoker group
were identiﬁed including TIMP1, APOA1, C6orf58, and BPIFB1 (LPLUNC1). In summary, our study demonstrates
that sputum proﬁling can capture the complex and reversible physiological response to cigarette smoke expo-
sure, which appears to be only slightly modulated in early-stage COPD.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The prevalence of chronic obstructive pulmonary disease (COPD), a
common lung disease, is estimated to be between 8% and 10% of the
adult population in developed countries [1], and theWorldHealthOrga-
nization (WHO) identiﬁed COPD as the third most common cause of
death in 2012 [2]. According to the chronic obstructive lung disease di-
agnosis and treatment guidelines (GOLD; http://www.goldcopd.com),
COPD is characterized as a lung disease with persistent airﬂow limita-
tion, which is usually progressive and incorporates both emphysema
and chronic bronchitis [3]. However, because of its complexity and var-
iability, it has been proposed recently that COPD is best regarded as a
syndrome rather than a single disease [4]. In the developed world, ciga-
rette smoking has been identiﬁed as the main risk factor for COPD de-
velopment and its progression [5–8]. For example, in a 25-year follow-
up study in Denmark it was found that the risk for continuous smokers
to develop COPD was at least 25% [9]. In addition to smoking, other risk
factors have been identiﬁed, including other sources of exposure. This is an open access article under(e.g., occupational exposure or air pollution) and genetic risk factors
(e.g., α1-antitrypsin deﬁciency) [1,10,11].
Initiation of COPD is only incompletely understood, but is clearly fa-
cilitated by smoke exposure [12–14]. In asymptomatic smokers, the re-
sponse of the lungs to smoke exposure includes an elevated oxidative
stress response, inﬂammation, and an increased mucus production
[15]. However, the lungs remain in homeostasis with, for example, suf-
ﬁcient redox capacity to deal with the oxidative stress and the ability to
keep the inﬂammatory response in check [16]. During development of
COPD, these normal, physiological, and inﬂammatory responses of the
lungs appear to be ampliﬁed, go further out of balance, and consequent-
ly result in more permanent chronic inﬂammation and structural lung
damage [3]. Consistent with this, it has been argued that the manifesta-
tion of COPD in long-term smokers representsmore a quantitative rath-
er than qualitative difference in the underlying biological effects [17];
i.e., at some point the physiological balancing mechanisms are at their
limits and permanent structural degradation follows. The exact transi-
tion point/thresholdwill likely be difﬁcult to deﬁne, but can be expected
to depend on general genetic susceptibilities and on time-dependent
processes that affect the coping potential of the tissue, such as develop-
ment of cellular senescence [18,19]. These points can be summarized inthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
307B. Titz et al. / Journal of Proteomics 128 (2015) 306–320a basic toxicant-exposure-to-disease-transition model for COPD (see
Section 4).
Several biological matrices have been explored to investigate effects
of respiratory toxicants and diseases on the human lung. The sampling
sources ranged from induced sputum to bronchoalveolar lavage ﬂuid to
lung biopsies [20,21] and, of these, induced sputum has the advantage
of being the least invasive and best tolerated technique, allowing for its
safe application in large study cohorts. Sputum is induced by inhalation
of hypertonic saline, and subsequently coughed up and collected for
analysis. Previous respiratory toxicology and lung disease studies investi-
gated alterations in the sputum proteome. The ﬁrst, published by Nicho-
las et al. [22], reported the protein components of a single smoker's
sputum using two-dimensional (2D) gel and LC–MS/MS analyses. In a
subsequent study, Nicholas et al. [23] analyzed a larger cohort of COPD
subjects (GOLD stages 1–3) and asymptomatic smokers using a 2D gel
approach. Gray et al. [24] employed SELDI-TOF for the identiﬁcation of
potential biomarkers for asthma, cystic ﬁbrosis, and COPD. Ohlmeier
et al. [25] analyzed seven non-smokers, asymptomatic smokers, and
COPD subjects with 2D difference gel electrophoresis and identiﬁed ele-
vated polymeric immunoglobulin receptor (PIGR) levels in COPD sub-
jects compared with asymptomatic smokers. In contrast, the number of
reported sputum transcriptomics studies is limited. For example, Singh
et al. [26] analyzed the sputum transcriptome proﬁles of former smokers
with COPD (GOLD stages 2–4) from the ECLIPSE study – a non-
interventional, observational, multicenter, three-year study in subjects
with COPD [27] – and identiﬁed signiﬁcant changes in genes associated
with the severity of airﬂow limitation and emphysema.
Here, we present results from a clinical case–control study with 60
age- and gender-matched individuals for each of the four study groups:
current asymptomatic smokers, smokers with early stage COPD, former
smokers, and never smokers (Fig. 1A). Speciﬁcally, in this manuscript
we focus on the question how cigarette smoke exposure, smoking ces-
sation, and the presence of early-stage COPD are reﬂected in the prote-
ome and cellular transcriptome of induced sputum samples.
2. Materials and methods
2.1. Subjects
In this study, we used a parallel-group case-controlled study design to
determine changes in the sputum proteome and transcriptome of
smokers with COPD, asymptomatic (no COPD) smokers (CS), asymptom-
atic (no COPD) former smokers (FS), and asymptomatic never smokers
(NS). The study was conducted between July 2011 and December
2012 at a single clinical site in London, UK, after approval from theNation-
al Health Service (NHS) Black County Ethics Committee and in strict com-
pliance with the International Conference on Harmonisation—Good
Clinical Practice (ICH-GCP) guidelines. The study has been registered on
ClinicalTrials.gov with identiﬁer NCT01780298.
Male and female subjects aged between 41 and 70 years were en-
rolled with a completed total subject number of 60 per group. If a sub-
ject discontinued participation (for medical or personal reasons), he/
she was replaced. During the course of the study, sputum, blood, and
nasal samples were collected and a number of physiological and clinical
measurements were recorded from a total of 240 subjects. Here, we re-
port on the ﬁndings for the sputum proteome and transcriptome. Sub-
jects in each of the three control groups (CS, FS, and NS) were
matched to subjects in the COPD group by age (±5 years), ethnicity,
and gender, and all smoking subjects had a smoking history of at least
10 pack-years. For this purpose, a match ID was deﬁned for each paired
group of four subjects.
2.2. Sputum collection
Sputum induction was performed at visit 1 (screening), visit 1a (at
the discretion of the investigator), and again at visits 2 and 4. At visit 1(and visit 1a), subjects underwent the sputum induction procedure to
conﬁrm that they were able to produce a sputum sample weighing at
least 0.1 g; this was an eligibility criterion for the study. Subjects unable
to produce an adequate induced sputum sample at visit 2 repeated the
procedure at visit 3.
All subjects with a forced expiratory volume in one second (FEV1) of
≥80% predicted and with no respiratory disease performed the sputum
induction procedure directly. Subjects with COPD or an FEV1 of ≤80%
predicted were administered 200 μg of salbutamol by metered dose in-
haler. The FEV1 was then assessed 15 min after salbutamol administra-
tion and subjects with a highest FEV1 value of ≥1.0 L or ≥50% predicted
could proceed to sputum induction.
Prior to sputum induction, the subject was asked to blow his/her
nose. Nasal passages were closed with a soft nose-clip and the subject
instructed to inhale 3% hypertonic sodium chloride solution over
5min. After inhalation or if able to expectorate before 5min had passed,
the subject was asked to blow his/her nose, gargle, and rinse their
mouth using room temperature water. The subject was then instructed
to cough up sputum, which was collected in a pre-labeled cup. Where
possible the subject was to complete three cycles of sputum expectora-
tion using 3%, 4%, and 5% hypertonic sodium chloride. Sputum from all
three cycles was collected in the same cup. If a subject's FEV1 fell ≥20%
of the best post-bronchodilator baseline value or if signiﬁcant symp-
toms were seen, sputum induction was stopped and the subject given
bronchodilator therapy as needed. Sputum samples were placed on
ice and processed within 2 h. Sputum plugs were selected and solubi-
lized inDTT, and the cell phasewas collected cytometry and transcripto-
mics evaluation by centrifugation while the supernatant was collected
in separate cryovials and stored at−80 °C until subsequent proteomic
analysis.
2.3. Proteomics analysis
Sputum samples from all 240 study subjects were processed in ran-
dom order. A reference sample was included by mixing equal protein
amounts of all 240 samples. Proteins were extracted by acetone precip-
itation and desalted, followed by trypsin digestion. The tryptic peptides
were labeled using TandemMass Tag™ 6-plex (TMTsixplex™) reagents
(Thermo Scientiﬁc, Waltham, MA, USA), and one labeled sample each
representing the four study groups plus the reference sample were
mixed in equal protein amounts. The paired subjects in each TMT set
were matched to the COPD sample by age, ethnicity, and gender (and
amatch IDwas assigned to each set). These labeledmixeswere then pu-
riﬁed to remove unincorporated TMT™ reagents and subsequently ana-
lyzed by liquid chromatography tandem mass-spectrometry (LC–MS/
MS) using an EASY-nanoLC 1000 instrument connected online to a Q
Exactive™mass-analyzer (Thermo Scientiﬁc). Peptideswere fractionat-
ed on a 50 cm C18RP RSLC EASY-spray™ column (2 μm particle size;
Thermo Scientiﬁc) at a ﬂow rate of 200 nL/min with a 200min gradient
from nanoLC buffer A (5% acetonitrile, 0.2% formic acid) to 40% acetoni-
trile, 0.2% formic acid. Each sample set was analyzed in duplicate in fast
and sensitive analysis mode as described previously [28]. LC–MS/MS
data from both injections were merged and compared against the
human reference proteome in the UniProt database (http://www.
uniprot.org/, version January 2014). Proteome Discoverer™ 1.4 (Ther-
mo Scientiﬁc) was used for the database searches with the SEQUEST™
HT and Mascot® 2.4 search algorithms. The Percolator node of Prote-
ome Discoverer™ was used to estimate peptide-level adjusted p-
values (q-values), and the peptides were ﬁltered for a q-value b0.05
(i.e., the false discovery rate (FDR) was controlled at the 5% level). The
quantiﬁcation of TMT™ reporter ions and the peptide-to-protein
(group) assignments was performed with Proteome Discoverer™.
TMT™ peptide-level data were exported and further processed in the
R statistical environment [29]. Quantitative data were ﬁltered for
“unique” quantitative results; e.g., by removing redundant results
from multiple search engines. To improve data quality, multiplexed
Fig. 1. Parallel-group case-controlled study design to determine proteome and transcriptome differences in COPD subjects, asymptomatic smokers, asymptomatic former smokers, and
asymptomatic never-smokers. (A) Schematic representation of the study design. Induced sputum samples were collected from 60 individuals in each study group (current smokers
[CS], stages I and IIa COPD subjects, former smokers [FS], and never smokers [NS]). COPD subjects were current smokers. Subjects in the COPD, CS, and FS groups had a smoking history
of ≥10 pack years. All groups were age and gender matched. Sputum samples were divided into the cellular fraction for transcriptomic analysis and the cell-free supernatant for quanti-
tative proteomic analysis. (B) Boxplot showing the median and quartile ranges of the lung function parameter FEV1 predicted for all study groups. (C) As in B, for the carbon monoxide
transfer factor (TLCO predicted). (D) Boxplot for the measured weights of the induced sputum samples. * indicates the p-values (Welch t-test) compared with NS were b0.05.
(E) Boxplot for the measured protein concentrations for the sputum supernatants (measured after protein precipitation). * indicates the p-values (Welch t-test) compared with NS
were b0.05.
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(interquartile range) or above the 75%ile + 1.5 IQR were classiﬁed as
outliers. With this, 216 out of 240 samples were retained for the subse-
quent analysis (54 of each group). Global variance stabilizing normali-
zation was performed [30,31]. Each TMT™ reporter ion set was
normalized to its median, and protein expression values were calculat-
ed as the median of these normalized peptide-level quantitation values
[32]. Only proteins quantiﬁed for at least 2/3 of the samples of each
study group were considered for differential abundance analysis. The
four subject groups (NS, CS, FS, and COPD) enabled six pairwise compar-
isons, for which the statistics of differential protein expressions were
calculated using the limma package [33]. For each comparison, a linear
model was ﬁtted to the expression data of the two considered subject
groups only, which further included a covariate variable (match ID) tak-
ing into account the 60 subject strata deﬁned in the study design. TheBenjamini–Hochberg (BH) FDRmethodwas used to correct formultiple
testing effects [33]. Proteinswith BH-adjusted p-values b0.05were con-
sidered as signiﬁcantly differentially abundant. The mass spectrometry
proteomics data have been deposited to the ProteomeXchange Consor-
tium [34] via the PRIDE partner repository with the dataset identiﬁer
PXD001977. Note that thedata for the full set of 240 samples is provided
and the 216 samples considered for the analysis presented here are in-
dicated in the “Comments [IncludedForAnalysis]” column in the sample
annotation ﬁle.
2.4. Generation of transcriptomics data
RNAwas extracted andprocessed byAROSApplied BiotechnologyA/
S (Aarhus, Denmark) and hybridized to Affymetrix Human Genome
U133 Plus 2.0 Arrays according to standard operating procedures. 192
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subjected to further data analysis in the R statistical environment [29].
Raw RNA expression data were ﬁrst preprocessed using the affy and
gcrma packages of the Bioconductor suite of microarray analysis tools
[33,35,36]. GeneChip Robust Multiarray Average (GCRMA) background
correction and quantile normalization were used to generate probe set-
level expression values [37]. Quality controls were then iteratively per-
formed using the arrayQualityMetrics package [38] to retain 179 valid
arrays. As for the proteomics analysis, the four subject groups (NS, CS,
FS, and COPD) enabled six pairwise comparisons, forwhich the statistics
of probe set-level differential expressions were calculated using the
limma package [33]. For each comparison, a linear model was ﬁtted to
the expression data of the two considered subject groups only, which
further included a covariate variable (match ID) taking into account
the 60 subject strata deﬁned in the study design. Probe set-level results
were attributed to the 23.414 HGNC gene symbols underlying our net-
work collection (see below) using thebest probe set-gene symbol anno-
tation determined by the overall lowest p-values in the six pairwise
comparisons. Raw p-values were then adjusted for multiple testing
using the Benjamini–Hochberg procedure [33]. Microarray data were
submitted to ArrayExpress with the accession number E-MTAB-3604.
2.5. Identiﬁcation of functional clusters
Functional association networks were derived for the differentially
abundant proteins or genes and functional association clusters were
identiﬁed to guide functional interpretation. The functional associations
between genes or proteins were obtained from the STRING database
(version 9.1) [39]. To identify functional protein clusters associated
with the current smoking status, functional associations with at least
medium conﬁdence (score N0.4) between the differentially up- (or
down-) regulated proteins in all smoker vs. non-smoker comparisons
(CS vs. NS, COPD vs. NS, CS vs. FS, COPD vs. FS) were extracted and clus-
ters were identiﬁed using an information theoretic approach for com-
munity identiﬁcation [40]. Functional annotation of the clusters was
guided by enrichment analysis with the TOPPGene tool [41]. To allow
for summarization of the transcriptomics data with a larger number of
differentially expressed mRNAs as a concise and interpretable associa-
tion network, we used the dnet approach [42]. With this, a concise
gene association network of about 100 nodes with maximized overall
differential expression for CS vs. NSwas identiﬁed. Cluster identiﬁcation
and annotation was performed as for the proteomics data. Network
analysis and visualization was supported by the igraph package in R
[43,44].
2.6. Network analysis for transcriptomics data
In order to interpret the transcriptomics results, we also applied a
systems biology approach called “Network Perturbation Amplitude”
(NPA), which uses the differential expression of predeﬁned sets of
genes (transcriptional layer) to deduce the changes in the activities of
the upstream biological mechanisms that collectively affect these
genes (functional layer) [45,46]. These mechanisms have been assem-
bled as so called backbone nodes into causal networkmodels describing
speciﬁc processes such as cellular stress and inﬂammatory responses
[47,48]. One advantage of the NPA approach is that the calculated per-
turbation amplitudes can be quantitatively contrasted across multiple
pairwise comparisons, very much like gene differential expression, but
at a higher level of the systems organization (backbone node or even
full network instead of single genes).
Because sputum samples containmultiple cell types (mostly macro-
phages and neutrophils) and because the relative proportions of these
multiple cell types can vary between the four subject groups (NS, CS,
FS, and COPD), care is neededwhen interpreting the changes in the spu-
tumcellular transcriptomes. In particular, this is of concernwhen apply-
ing the cell type-speciﬁc inﬂammatory network models [47], whichimplicitly assume that the changes in the cellularmRNA can be attribut-
ed to the differential regulationwithin one cell type. Thus, we calculated
the NPA values at the level of the individual backbone nodes in a net-
work model-independent manner by applying the so called strength
metric. Comparing these NPA results and gene expression changes for
our study with published datasets on the gene expression response of
macrophages (see below) enabled us to determine which cell type-
speciﬁc inﬂammatory network models were applicable for a given
pairwise comparison. The appropriatemodelswere then used to identi-
fy biological processes that likely caused the changes observed in the
sputum transcriptomes.
The public gene expression datasets (Supplementary Table S3)were
downloaded from the Gene Omnibus (GEO) database and preprocessed
as described above for our data. The downstream genes (i.e., the tran-
scriptional layer) that are connected to the backbone nodes of the cellu-
lar stress and inﬂammation network models used in the NPA
calculations were extracted from the Selventa Knowledgebase, which
is a comprehensive repository containing over 1.5 million nodes and
over 7.5 million edges [45]. The Selventa Knowledgebase is derived
from peer-reviewed scientiﬁc literature as well as other public and pro-
prietary databases — a part of which is publicly available through the
openBEL portal [www.openbel.org]. The GSEA calculations were run
on a local installation of the analysis software [49].
2.7. Identiﬁcation of discriminant predictive proteins
A discriminant set of proteins for a given comparison (e.g., CS vs. NS)
were derived either by logistic lasso regression [50] or by linear discrim-
inant analysis (LDA) with a forward selection procedure [51]. The for-
ward selection is aiming at ﬁrst ﬁnding the most discriminant protein
(by leave-one-out cross-validation) by testing all the available ones
using LDA, then subsequently test for the second best (together with
the ﬁrst selected one) and so on, until having included N proteins,
where N is speciﬁed by the user based on the expected complexity of
themodel. The regularization parameter for the logistic lasso regression
was selected by 10-fold cross-validation. The performance of each pro-
cedurewas evaluated by k-fold cross validation, repeated L timeswhere
k = 10 and L = 5.
3. Results
3.1. Study population and sputum sampling
To assess how smoking and mild COPD disease are reﬂected in the
sputum proteome and transcriptome, we collected induced sputum
from four study groups: early-stage COPD subjects (GOLD stage 1–2
and current smokers) (COPD), current smokers without COPD disease
(CS), never smokers (NS), and former smokers (FS). The rationale was
to cover all relevant transitions during the early course of the disease.
Each cohort (n= 60)wasmatched by age (within 5 years) and gender,
and individuals were required to have a smoking history greater than
10-pack years (except for never smokers). Former smokers had quit
for at least 1 year prior to the start of the study (Fig. 1A, Table 1). Impor-
tantly, our selection criteria were different from other related studies
such as the ECLIPSE study [27,52]: we selected only subjects with mild
and moderate COPD (29 GOLD stage 1, 31 GOLD stage 2) and subjects
with recent infections or a history of exacerbations of COPD were ex-
cluded. FEV1% predicted and the transfer factor for carbon monoxide
(TLCOpredicted) exemplify the decline in lung function in the COPD co-
hort (Fig. 1B/C). The exclusion of subjects with a recent history of
infections or exacerbations of COPD likely explains why we did not ob-
serve the previously reported increase in neutrophil percentages for the
COPD andCS groups in our study population (Supplementary Figure S1)
[53,54]. However, recent reports have indicated that this association
may be less consistent and possibly more tightly linked to a current ac-
tive inﬂammatory process rather than COPD as a whole [55].
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groups. As expected, more sputum was obtained from current smokers
(CS and COPD), especially COPD subjects, than fromNS and FS (Fig. 1D).
Conversely, sputumproteinsweremore diluted, when sampled fromCS
and COPD than from NS and FS groups (Fig. 1E).
3.2. Sputum proteome and transcriptome reﬂect smoking and COPD status
Induced sputum samples were collected from all 240 study partici-
pants, the cell-free supernatantwas subjected to TMT™-basedquantita-
tive proteomic analysis, and the cellular sputum fraction was subjected
to microarray-based transcriptomic analysis. For proteomic analysis, 54
subjects in each group remained after quality ﬁltering (i.e., 216 in total)
(seeMethods).We used a normalization procedure that corrects for the
observed intensity difference between the sample groups to focus on
the protein abundancedifferenceswithin the sputumproteome fraction
accessible to mass-spectrometry analysis. For the transcriptomic analy-
sis, 179 samples remained after quality ﬁltering.
Differentially abundant sputum proteins and mRNAs between the
study groups were identiﬁed (FDR-adjusted p-value b0.05). Volcano
plots of effect size and signiﬁcance showed clear differences between
the smoker (CS and COPD) and non-smoker (FS and NS) groups for
both the proteomics and the transcriptomics data (Fig. 2A/B, Supple-
mentary Table S1). Among the affected proteins, aldehyde dehydroge-
nase 3A1 (ALDH3A1) showed the strongest and most signiﬁcant
increase in the smoker groups (CS and COPD) and, strikingly, was by it-
self sufﬁcient to accurately predict the current smoking status of the
study subjects (Supplementary Fig. 2). In contrast, the FS and NS groups
demonstrated limited statistically signiﬁcant differences in protein ex-
pression with only the S100 calcium binding protein A6 (S100A6)
showing signiﬁcantly lower abundance in FS than in NS. No differential-
ly expressed mRNAs between the early-stage COPD and the CS groups
were identiﬁed. However, 13 proteins were differentially abundant be-
tween these two groups, which provided the ﬁrst evidence for COPD-
speciﬁc effects in the induced sputum samples (discussed below).
Importantly, for both the proteomics and transcriptomics data,
pairwise comparisons between the groups showed a high correspon-
dence between all four current smoker vs. non-smoker group compari-
sons (CS vs. NS, CS vs. FS, COPD vs. NS, and COPD vs. FS) (Fig. 2C/D).
With this, the current smoking status of the study subjects clearly dom-
inated the observable effects in the induced sputum proteome and
transcriptome.
3.3. Smoking is reﬂected by the activation of several compensatory mecha-
nisms and a change in immune cell polarization
Several compensating mechanisms are activated in asymptomatic
current smokers that allow maintenance of homeostasis and prevent
manifestation of disease. To assess which of these mechanisms mightTable 1
Characteristics of study subjects.
Early-stage COPD subjects Asymptomatic
Group label COPD CS
N (before/after ﬁlter) 60 60
Age (years) 57.17 (±7.16) 55.31 (±6.91)
Male:female ratio % 60:40 53:47
Pack years 44.0 (10.0–117.5) 25.5 (10.0–70.
Years in cessation 0 0
BMI kg/m3 26.46 (±3.7) 27.33 (±3.56)
Alcohol units/week 6.69 (±7.66) 5.92 (±6.31)
FEV1% predicted 75.28 (43.05–115.50) 101.35 (73.85–
Diastolic blood pressure (mm Hg) 73.5 (57–92) 71.0 (61–92)
Systolic blood pressure (mm Hg) 121.0 (90–148) 121.0 (93–147
Heart rate (bpm) 70.0 (44–101) 68.0 (50–95)
Respiration rate (breaths per min) 15.0 (11–19) 15.0 (11–20)
FVC, forced vital capacity; FEV1, forced expiratory volume in the ﬁrst second; BMI, Body Mass Ibe detectable in our induced sputumdata, we identiﬁed functional clus-
ters enriched for differentially abundant proteins and differentially
expressed mRNAs (Fig. 3A and B, Supplementary Figure S3). To com-
pensate for the lower number of proteins quantiﬁed by proteomics
and to maximize sensitivity, we considered all differentially abundant
proteins between the current smoker (CS/COPD) and current non-
smoker (NS/FS) groups.
Several functional protein clusters affected by cigarette smoke expo-
sure were identiﬁed in the sputum proteome (Fig. 3A). These included
mucin/trefoil proteins (e.g., MUC5AC and TFF1/3), xenobiotic metabo-
lism enzymes (e.g., ALDH3A1, NQO1, and GSTA1), peptidase regulators
(e.g., TIMP1 and SERPINB1), and proteins involved in redox processes
(e.g., TXN, PRDX1, and SOD1). Among the down-regulated clusters
were likely blood plasma-derived proteins (e.g., ALB, APOA1, and TF)
and immunoglobulins (e.g., IGHG1-4 and IGKC).With this, the observed
effects in the sputum proteome reﬂect several of the main known ef-
fects of cigarette smoke exposure including the xenobiotic and oxida-
tive stress response, changes in mucin production, and alterations in
the protease balance [56–58].
The functional clusters identiﬁed for the differentially expressed
mRNAs in sputum cells (CS vs. NS) included xenobiotic and oxidative
stress (e.g., CYP1B1, NQO1, and GSR) and immune-related (e.g., CXCL10,
CXCL11, and GBP4) gene clusters (Fig. 3B). Whereas the xenobiotic and
oxidative stress cluster contained mainly up-regulated mRNAs and thus
reﬂected a common exposure response, the mostly down-regulated
immune-related cluster required further investigation. We noted that
the most strongly enriched pathway for this down-regulated cluster
was the interferon signaling pathway (Reactome database (http://www.
reactome.org/), q-value (BH)=5.8E−10, ToppGene tool [41]). In further
support of the down-regulation of interferon signaling, several binding
sites for interferon-regulatory factors and an interferon gamma gene set
were signiﬁcantly negatively enriched in the CS vs. NS comparison in a
gene set enrichment analysis (Supplementary Table S2).
To better understand the above described exposure response of the
sputum cell population, we compared the sputum transcriptomics data
with ﬁve public data sets (Fig. 3C, Supplementary Table S3). These stud-
ies analyzed the smoke exposure response of alveolarmacrophages and,
interestingly, they all showed a positive correlation and a signiﬁcant
overlap of the differentially expressed genes with our study (Fisher's
test p-value b0.05). This similarity suggested that macrophages were
the main drivers of the changes observed in our sputum mRNA data
and enabled us to employ a previously published causal macrophage
activation network to better understand the response of these cell pop-
ulations [47]. Except for one data set (GEO: GSE27002) all others dem-
onstrated signiﬁcant perturbation of the macrophage activation
network as a whole (Supplementary Fig. 4 and 5) [45]. In addition,
and further supporting our observation of altered IFN signaling in
smokers compared to never-smokers, a major shared component of
this network response was the down-regulation of the interferonsmokers Asymptomatic never smokers Asymptomatic former smokers
NS FS
60 60
55.46 (±7.45) 56.34 (±7.39)
57:43 58:42
0) 0 31.0 (10.3–75.0)
0 8.85 (1.06–44.3)
26.48 (±3.72) 27.33 (3 ± 3.56)
5.78 (±6.71) 8.45 (±7.10)
129.10) 112.35 (79.20–151.05) 109.05 (73.85–129.10)
72.0 (56–88) 72.0 (56–92)
) 122.0 (94–179) 123.5 (101–151)
62.0 (43–91) 66.0 (43–101)
16.0 (11–20) 15.0 (11–20)
ndex; bpm, beats per minute. Data are presented as mean (±SEM) or as median (range).
Fig. 2. Sputum proteome and transcriptome reﬂect the smoking status. (A) Volcano plots showing the magnitude (log2 fold-change) and signiﬁcance (−log10 Benjamini–Hochberg ad-
justed p-value) of differential sputumprotein expression for the six indicated group comparisons. Signiﬁcantly up-regulated proteins aremarked in red, signiﬁcantly down-regulated pro-
teins aremarked in blue (adjusted p-value b0.05). Note that 13 proteins were differentially abundant between the COPD and CS groups. (B) Volcano plots showing the differential mRNA
expression in sputum cells. Signiﬁcantly up-regulatedmRNAs aremarked in red, signiﬁcantly down-regulatedmRNAs aremarked in blue (adjusted p-value b0.05). (C) Comparison chart
for the differentially abundant sputum proteins. The correlation coefﬁcient for the comparisons is color-coded, and the number of shared differentially expressed proteins is indicated
(total numbers in the margins). The pie charts show the percentage of shared differentially abundant proteins with the same direction of fold change (FC sign). The green * indicates
the observed overlap of the differentially abundant proteins was signiﬁcant. (D) Comparison chart for the differentially expressed mRNAs. Other details are the same as those in (C).
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work analysis supported up-regulation of STAT3 activity upon smoke
exposure.
Strikingly, IFNG and STAT3 have been associated with different
macrophage polarization states: IFNG with M1 and STAT3 with M2 po-
larization [59] andmacrophage polarization changes upon smoke expo-
sure have already been reported for the compared studies [60,61].Speciﬁcally, Shaykhiev et al. (GEO: GSE13896) found that alveolar mac-
rophages of smokers “exhibited a unique polarization pattern character-
ized by substantial suppression of M1-related inﬂammatory/immune
genes and induction of genes associated with various M2-polarization pro-
grams” [60]. When we directly assessed the behavior of the M1- and
M2-phenotype-related genes deﬁned by Shaykhiev et al. [60], we
found a surprisingly high correspondence between the response of
Fig. 3. Sputum proteome and transcriptome reveal biological effects of cigarette smoke exposure. (A) Functional protein clusters identiﬁed for themain smoke exposure effect by sputum
proteomics. A functional association database (STRING database [39]) was queriedwith all signiﬁcantly up- (top panel) or down- (bottom panel) regulated proteins in the smoker (COPD
or CS) vs. non-smoker (NS or FS) groups. The identiﬁed association networks were clustered to guide functional interpretation. The identiﬁed clusters are marked and those with a clear
biological function are annotated. The color of the nodes (proteins) represents the signed−log10 adjusted p-value of the CS vs. NS group comparison. (B) Functional gene clusters iden-
tiﬁed for themain smoke exposure effect by sputum transcriptomics. The dnet algorithmwas used to identify an “activated” functional association subnetwork for the CS vs. NS compar-
ison [42]. Other details are similar to (A). (C) Comparison ofmRNA response in sputum samples (CS vs. NS) and ﬁve alveolarmacrophage exposure studies (Supplementary Table S3). The
CS vs. NS effect on the transcriptome is compared. The Pearson correlation coefﬁcient for the observed fold-changes is color-coded; the number of detected and shared differentially
expressed genes is indicated together with the fraction of fold-changes that show the same direction. (D) Network perturbation amplitude (NPA) values for the backbone nodes of the
macrophage activation network. Nodes with a signiﬁcant NPA value in the sputum cell CS vs. NS comparison are shown (rows). The NPA for these nodes is compared across studies (col-
umns, see color key) and rescaled by the value for sputum cells. “*” denotes signiﬁcance; p-value b0.05 for both uncertainty and speciﬁcity statistics [45]. (E) Volcano plots showing the
cellular mRNA expression changes in the CS vs. NS groups for the M1- and M2-related genes as deﬁned by Shaykhiev et al. [60]. Signiﬁcantly up-regulated genes are marked in red, sig-
niﬁcantly down-regulated genes are marked in blue (adjusted p-value b0.05). (F) Fold-change comparison between the quantiﬁed sputum proteins and cellular sputummRNAs (CS vs.
NS). Signiﬁcant differential protein abundance for CS vs. NS is indicated by large black dots (otherwise small gray dots). Signiﬁcant differential mRNA expression for CS vs. NS is indicated
by black triangles. Proteins/mRNAswith signiﬁcant differential changes in both data sets are labeled. (G) Fold-change comparison between differentially abundant proteins in sputumand
differentially expressedmRNAs in the expression data set for the large airways epithelium (both current smokers vs. non-smokers, GEO: GSE10135[62]). Other details are similar to those
in (E).
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pled by sputum induction (Fig. 3D, Supplementary Fig. 7); i.e., based
on the M1/M2-signature genes the sputum cell population in current
vs. never smokers clearly shifted from an M1 to an M2 phenotype. Im-
portantly, these results also conﬁrmed the relevance of macrophage-
based mechanisms for the interpretation of the cigarette smoke expo-
sure effect and the relevance of the “macrophage activation” model in
our network analysis [47].
Finally, we asked how the observed differences in protein
abundance relate to changes in mRNA expression. Because we sampled
different sputum fractions for proteomics (supernatant) and tran-
scriptomics (cellular fraction), we expected a limited overlap (Fig. 3F).
However, in linewith the functional cluster analysis, the genes encoding
the main up-regulated oxidative/xenobiotic stress response proteins
that were detected in the cellular fraction (ALDH3A1 and NQO1) were
also found in sputum supernatant. Sputum proteins are derived from
different sources including from secretory cells in the epithelium.
Thus, we compared the signiﬁcantly differentially abundant sputum
proteins with differentially expressed genes in the large airway epithe-
lium of smokers (GEO: GSE10135[62]) and found that ﬁve of the nine
shared up-regulated proteinswere oxidative/xenobiotic stress response
proteins (e.g., ALDH3A1, NQO1, and TXN) (Fig. 3G). Another example of
a shared up-regulated sputum protein was SPRR3, which is a compo-
nent of the corniﬁed cell envelope of stratiﬁed squamous epithelia
[63]. With this, increased abundance of SPRR3 likely reﬂects the devel-
opment of squamous metaplasia in smokers [64,65].
In summary, the sputum proteome and transcriptome reﬂected sev-
eral of the biological effects of cigarette smoke exposure. Induction of
the xenobiotic/oxidative stress response was shared between all com-
partments. In addition, the sputum proteome reﬂected alterations in
mucus production and protease regulation and the transcriptome indi-
cated a polarization ofmacrophages from theM1 toward theM2 state in
the sputum cell population.
3.4. Long-term smoking cessation results in attenuation of exposure effects
in sputum
Smoking cessation is the most effective measure to prevent COPD
and to slow its progression [8,13]. It is known that upon smoking cessa-
tion the majority of observable exposure effects return to baseline
levels: The oxidative stress response reverts within a year [66], modula-
tion of the inﬂammatory state in the lung reverts on a similar time-scale
[67], but an increased lung cancer risk is detectable for decades after
smoking cessation [68]. In this study, subjects in the FS group had quit
smoking for at least 12 months prior to the start of the study, and the
majority (approximately 78%) had quit for more than ﬁve years. Thus,
we asked to what extent the observed cigarette smoke exposure-
related changes were still detectable in this long-term cessation group.
We detected only one differentially abundant protein (S100A6) and
no differentially expressed transcripts between the FS and NS groups
(Fig. 2A and B). Since this assessment depended on the chosen p-
value threshold, we complemented it with a direct comparison of the
observed fold-changes for the CS vs. NS and FS vs. NS comparisons
(Fig. 4A and B).We expected a slope close to zero if the exposure effects
in former smokers largely approached non-smoker levels, and this was
indeed the case for both the proteomics and transcriptomics data (al-
though a slightly increased slope was still observed for the proteomics
data set). For example, the two highest up-regulated (xenobiotic/oxida-
tive stress) proteins in CS vs. NS, ALDH3A1 and NQO1, exhibited lower
levels in the FS than in the NS group.
When the identiﬁed biological effects in FS relative to NS were com-
pared with those in CS relative to NS, a similar picture for both data
types was obtained (Fig. 4C). The observed changes in the current
smoker proteome including the mucin/trefoil proteins, the xenobiotic/
oxidative stress response proteins, and the peptidase regulator cluster
largely approached NS levels in the FS group. Interestingly, in thetranscriptomics analysis the (interferon-related) immune-response
cluster even demonstrated a slight up-regulation in the FS vs. NS com-
parison. This observation was further corroborated by the comparison
of network perturbation amplitudes, which demonstrated an overall
deactivation of the xenobiotic metabolism response, but a partial inver-
sion of macrophage activation for FS vs. NS compared to CS vs. NS
(Fig. 4D). For example, FS vs. NS showed an increase rather than a de-
crease in the NPA of the IFNG and the NFkB complex nodes (Fig. 4E),
which for IFNG signalingwas further supported by gene-set enrichment
analysis (Supplementary Fig. 6). IFNG and NFkB signaling have been as-
sociated withM1 polarization [59] and – together with the gene set en-
richment results for the M1-associated gene set (Supplementary Fig. 7)
– this supports a persistent (but inverted) effect on the polarization of
macrophages toward a M1 phenotype in the FS sputum.
In conclusion, the characteristics of both the sputum proteome and
transcriptome of former smokers largely approached those seen in
never-smokers. Nevertheless, some long-term effects of cigarette
smoke exposure remained noticeable in former smokers' sputum as in-
dicated by the increase in IFNG and NFkB signaling, which are both as-
sociated with a M1 polarization of the FS sputum cell population.
3.5. Early-stage COPD subjects demonstrate quantitative differences in
sputum
A main question of this study was whether sputum samples reﬂect
airway changes associated with early stages of COPD. A total of 13 spu-
tum proteins demonstrated differential abundance between subjects
with early-stage COPD and those that were asymptomatic (FDR-adjust-
ed p-value b0.05, Fig. 5A). These 13 proteins showed a reasonable cor-
relation with the FEV1% predicted, which is in line with previous
studies [23], and the carbon monoxide transfer factor (TLCO predicted)
(Fig. 5B). The differential abundance of several of these 13 proteins has
been linked previously to COPD or other lung diseases (Table 2); for ex-
ample, increased abundance of TIMP1 (metalloproteinase inhibitor 1) in
sputum [69,70] and decreased abundance of AHSG (alpha-2-HS-glyco-
protein) [23] and ALB (serum albumin) [23,71] have been reported.
To expand the data comparison, we also evaluated the observed
trends for the COPD-associated sputum proteins reported by Nicholas
et al. [23] (Supplementary Fig. 8). Although they did not reach statistical
signiﬁcance in our study, all the proteins showed a consistent trend for
the COPD subjects. For example, lipocalin 1 (LCN1) and transthyretin
(TTR) showed lower and cystatin C higher abundance in COPD subjects;
MSMB (PSP94) also shows slightly higher abundance in the COPD
group, but in our study the dominant effect was an increase in both
smoker groups (COPD and CS).
The comparison across all study groups indicated that the sputum
levels generally exhibited a gradient fromNS/FS to CS to COPD subjects;
that is, proteins that were already overabundant in asymptomatic
current smokerswere further increased in COPD smokers (Fig. 5C). Fur-
thermore, this observation of a general ampliﬁcation of the CS effects in
COPD subjects for the sputum proteome was also supported by a more
global regression model in which the observed fold-changes for CS vs.
NS and COPD vs. NS were compared and demonstrated a slope signiﬁ-
cantly larger than one (Fig. 5D).
The transcriptomics analysis of the cellular sputum fraction did not
reveal any signiﬁcantly differentially expressed mRNAs between the
COPD and CS groups (Fig. 2B). Furthermore, a direct mRNA fold-
change comparison for CS vs. NS and COPD vs. NS showed a trend to-
ward global reduction of the CS effects in COPD subjects (Fig. 5E). De-
spite this global trend, several mRNA changes remained close to the
diagonal, i.e. were only slightly different between CS and COPD. Similar-
ly, a direct comparison of themRNA abundances for the three identiﬁed
main effects in CS, xenobiotic/oxidative stress response, M1 phenotype
suppression, and M2 phenotype induction, did not show any clear
trends between the CS and COPD groups (Fig. 5F). Interestingly, where-
as the NPA analysis further supported that there is little change in
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macrophage activation comparing CS vs. NS and COPD vs. NS was ob-
served (Fig. 5G). Speciﬁcally, nodes associated with M1 polarization
(e.g., IFNG and the NFkB complex) showed less down-regulation in
COPD vs. NS than CS vs. NS (Fig. 5H), and a similar trendwas supported
by gene set enrichment analysis (Supplementary Fig. 7). With this, the
previously observed (weak) trend of a further immune-cell polarization
in COPD (fromM1 toward M2) [60], was not found in our study, which
can likely be explained by the different subject and cell populations in
our study.
In addition,we can cautiously interpret the deviations of the sputum
results from themacrophages values obtained from the GEO:GSE13896
dataset by sputum-speciﬁc effects, such as mechanisms taking place in
neutrophils, for which appropriate models are also available [47].
Fig. 5I shows that the backbone nodes contained in the neutrophil che-
motaxis network model were on average higher in the COPD vs. NS
than in the CS vs. NS pairwise comparison. Given the very simple struc-
ture of this networkmodel that is causally consistent [45] and that con-
tains almost exclusively activation edges, these observations indicate a
signiﬁcant increase of the chemotactic activity of the sputum neutro-
phils, conﬁrmed by NPA network-level calculation (not shown) and ex-
empliﬁed by the positive value of the leukotriene B4 receptor (LTB4R)
node [72]. With this, despite the weakness of the signal at individual
gene-level, our network analysis was able to detect suggestive mecha-
nisms accompanying the onset of COPD.
In summary, the sputum proteome reﬂected differences between
current asymptomatic smokers and smokers with COPD. Strikingly, it
was possible to distinguish COPD and CS subjects based on the proteo-
mics data with a similar accuracy as based on the combination of
three lung-function COPD metrics (FEV1 pred., TLCO % predicted, and
total COPD score) (Supplementary Fig. 9). In contrast, mRNA expression
levels in sputum cells were similar between COPD and CS for the iden-
tiﬁed main biological effects and globally the mRNA differences were
dampened rather than exaggerated in COPD vs. CS.
4. Discussion
In this study, we employed a parallel-group case-controlled study
design to assess how the free sputumproteome and the cellular sputum
transcriptome reﬂected cigarette smoke exposure, smoking cessation,
and are affected by the presence of early-stage COPD. While – with
this study design–wedid not directly follow the individual exposure re-
sponse and disease onset, we evaluated to what degree the alterations
observed in the sputum samples overall supported a general toxicant-
exposure-to-disease-transition model for COPD (Fig. 6). This model is
based on the observation that COPD initiation clearly is facilitated by
long-term cigarette smoke exposure, smoking cessation is the most ef-
fective measure to reduce the risk of COPD development, and observ-
able biological responses in asymptomatic smokers (e.g., increases in
oxidative stress and inﬂammation in the lung) intersect with the
identiﬁed COPD disease mechanisms that eventually result in chronic
inﬂammation and structural lung damage [3]. The lungs of asymptom-
atic smokers still have sufﬁcient biological buffering capacity to, for ex-
ample, cope with the oxidative and xenobiotic challenges of cigarette-
smoke exposure — effects such as up-regulation of oxidative stressFig. 4. Effect of long-term smoking cessation on the sputumproteome and transcriptome. (A) Fo
Proteinswith signiﬁcant differential abundance for CS vs. NS are indicated by large black dots. A
are given (dashed, red line; gray conﬁdence range). (B) Fold-change comparison between CS vs
(A). (C) Comparison of the identiﬁed functional clusters/biological effects for CS vs. NS and FS vs.
data. The clustered association networks from Fig. 3 are overlaid with the log2 fold-changes of t
(NPA) scatter plot comparisons for CS vs. NS and FS vs. NS for the backbone nodes of the xenobio
95% conﬁdence range of the NPA values. The Pearson (rP) and Spearman (rS) correlation coefﬁ
ﬁdence range) are indicated. (E) NPA values for the backbone nodes of themacrophage activati
vs. NS comparison are shown (rows). The NPA for these nodes is compared for the three study g
signiﬁcance; p-value b0.05 for both uncertainty and speciﬁcity statistics [45].response proteins are observable, but still reﬂect the physiological and
reversible stress response. However, in many cases this homeostatic
state cannot be maintained and accumulating structural damage ini-
tiates the manifestation of the disease. For this, the transition point
will depend on genetic susceptibilities and on time-dependent pro-
cesses (e.g., development of cellular senescence) that affect the po-
tential of the tissue to handle the insult [18,19].
The sputum proteome and transcriptome clearly reﬂected some of
the main biological effects of cigarette smoke exposure previously
seen in other studies. Prominent xenobiotic metabolism and oxidative
stress responses were detected for both sputum fractions as would be
expected for cigarette smoke exposure [73,74]. For example, one of
these proteins, ALDH3A1, recently was reported to be up-regulated in
epithelial liningﬂuid of asymptomatic vs. never-smokers andwas clear-
ly associated with smoking status [75]. Here, sputum ALDH3A1 protein
levels supported the accurate prediction of the study subjects' smoking
status. Interestingly, in the present study, the up-regulated transcripts
included genes that encode several metabolic enzymes (e.g., glucose-6-
phosphate dehydrogenase (G6PD) and phosphogluconate dehydroge-
nase (PGD)) that likely contribute to the regeneration of NADPHas an im-
portant component of the oxidative stress response [76,77]. Other
relevant detected changes in the sputum proteomes of current smokers
included a change in mucus production (e.g., up-regulation of MUC5AC
and trefoil factors 1/3) and up-regulation of TIMPmetallopeptidase inhib-
itor 1 (TIMP1).
The detection of several xenobiotic and oxidative stress enzymes in
the sputum supernatant raised a question about their source, and espe-
cially, whether these enzymes could play an active role in the mucus
layer as a ﬁrst line of defense against xenobiotic and oxidative chal-
lenges. Normal epithelial lining ﬂuid has been found to contain high
levels of reduced glutathione, which are further increased in smokers,
and it has been suggested that this may provide extracellular protection
against oxidative challenges [78]. In addition, an important role for
transferrin in epithelial lining ﬂuid for protection against lipid peroxida-
tion has been identiﬁed [79]. Moreover, extracellular superoxide dis-
mutase was found to be increased in sputum samples of current
smokers and COPD subjects [80]. ALDH3A1 is an abundant detoxiﬁca-
tion enzyme in human cornea, its potential role in extracellular detoxi-
ﬁcation reactions has been demonstrated for human saliva [81,82], and
it has been detected recently as a component of the epithelial lining
ﬂuid (see above). Together these ﬁndings suggest the active contribu-
tion of these detoxiﬁcation enzymes as a ﬁrst line of defense in the
mucus layer/epithelial lining ﬂuid of the airways.
An interesting observation from the transcriptomics data was the
change in the apparent polarization of the overall sputum cell popula-
tion from an M1 toward an M2 phenotype (Fig. 3D, Supplementary
Fig. 7). Such a polarization shift was reported by Shaykhiev et al. for al-
veolar macrophages from asymptomatic smokers [60], and it has been
suggested that such a shift could affect disease susceptibility [83] in-
cluding that for lung cancer [84]. Furthermore, our network analysis
(Supplementary Fig. 5) supported the notion that this suppression of
the M1 phenotype is associated with the deactivation of several up-
stream signaling mechanisms (e.g., STAT1, TNF, and TLR3/4 signaling),
which likely results in the down-regulation of NFkB and IFNg signaling
as major transcriptional regulators of the M1 phenotype [59].ld-change comparison between CS vs. NS and FS vs. NS for the quantiﬁed sputumproteins.
linear regression line is ﬁtted for these proteins and the slope and 95% conﬁdence interval
. NS and FS vs. NS for the sputum transcriptomics data. Other details are similar to those in
NS for the sputumproteomics (top panel) and the sputum transcriptomics (bottompanel)
he proteins/mRNAs for the considered comparisons. (D) Network perturbation amplitude
tic metabolism response and themacrophage activationnetworks. The error bars indicate the
cients and the intercept and slope of the linear regression model (including the 95% con-
on network. Nodes with a signiﬁcant NPA value in the sputum cell CS vs. NS, CS vs. FS, or FS
roup contrasts (columns, see color key) and rescaled by the value for CS vs. NS. “*” denotes
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to reduce COPD morbidity and progression [13,85]. In our study, the
subjects in the FS group had quit smoking for at least 1 year and thema-
jority (78%) had quit for at least 5 years. In this cessation group, the ob-
servable smoking exposure effects in the sputum proteome and
transcriptome had largely approached the levels of the subjects in the
NS group (Figs. 2A/B, 4, 5E), including the oxidative and xenobiotic
stress response and the changes in mucin/trefoil proteins. The polariza-
tion changes in the sputum cell population had also largely reverted
(Fig. 5E), but interestingly some signs of a persistent (opposite) immune
cell polarization toward M1with increased INFG signaling were notice-
able (Fig. 4, Supplementary Fig. 7). Cessation studies reported in the lit-
erature often look at shorter time frames. For example, Wozniak et al.
[86] investigated the effect of 1–3 months of smoking cessation on the
oxidative stress parameters in COPD subjects and found that even
three months of smoking abstinence had partly restored the oxidant–
antioxidant balance in plasma and erythrocytes. In another study, plas-
ma markers of oxidative stress were still elevated after 6 months, but
not signiﬁcantly different from non-smokers after 12 months of
smoking cessation [66]. In line with our results, the cessation effect on
inﬂammation is more complex. For example, Willemse et al. [87] inves-
tigated the effect of 1-year smoking cessation on airway inﬂammation
and found perpetuation of inﬂammation after smoking cessation in
COPD subjects and reduction of some aspects of inﬂammation in
asymptomatic smokers.
Thirteen proteins had signiﬁcant differential abundance in the spu-
tum of early-stage COPD subjects compared to the CS group (Fig. 5,
Table 2). The majority of these proteins already showed signs of a con-
cordant regulation in the CS group compared with the NS group
(Fig. 5C). We also found evidence that the effects observed for the
sputum proteome of COPD subjects generally could be regarded as a
(slight) ampliﬁcation of the smoke exposure effects before disease de-
veloped (Fig. 5D). Interestingly, the sputum transcriptome did not re-
veal any signiﬁcantly differentially regulated transcripts between the
COPD and CS group and the identiﬁed biological effects were not in-
creased in the COPD compared to the CS group; on the contrary, an op-
posite global trend in themRNA expression levelswas detected (Fig. 5E/
F). These observations lend support to themodel that early-stage COPD
disease represents a manifestation of the chronic toxicant exposure ef-
fects (e.g., facilitated by shifts in stress response balances) rather than
a distinct, separate disease entity (see above and Fig. 6).
Previous studies of the sputum proteome of COPD subjects include
the 2D-gel based proteomics studies by Ohlmeier et al. and Nicholas
et al. [23,25,88]. Ohlmeier et al. [25] identiﬁed polymeric immunoglob-
ulin receptor (PIGR) as an up-regulated protein in asymptomatic
smokerswith further elevation in smokers with COPD disease.Whereas
differential PIGR expression did not reach signiﬁcance in our study after
multiple-hypothesis correction, a tendency for increased abundance in
COPD subjects was observed (p-value (COPD vs. CS) = 0.08, p-value
(COPD vs. NS)= 0.04, Supplementary Figure S8).With a study by Nich-
olas et al. [23], signiﬁcant down-regulation of the candidate biomarkersFig. 5. Sputumproteome shows a difference between COPD subjects and current smokers. (A) F
groups. The log2 fold-change is color coded. “*” indicates statistically signiﬁcant differential abu
predicted (top panel) and TLCOpredicted (bottom panel) for the 13 differentially abundant pro
coefﬁcient of determination (R2) for each protein. (C)Median relative protein abundance value
dant proteins in theCOPDvs. CS comparison.Up-regulatedproteins are in red, down-regulatedp
dashed line. (D) Fold-change comparison between CS vs. NS and COPDvs. NS for the quantiﬁed s
by a large black dot. A linear regression line is ﬁtted for these proteins and the slope and 95% con
parison between CS vs. NS and COPD vs. NS for the quantiﬁed sputum transcriptomics data. Oth
compared with the never smoker group (NS) for the differentially abundant proteins in the C
Fig. 3D), and genes in the xenobiotic/oxidative stress cluster (see Fig. 3B). Other details are simil
data for CS vs. NS and COPD vs. NS for the backbone nodes of the xenobiotic metabolism response
of the NPA values. The Pearson (rP) and Spearman (rS) correlation coefﬁcients and the interce
cated. (H) NPA for the macrophage activation network for the sputum transcriptomics data an
macrophage activation networkwith a signiﬁcant NPA value in the sputum cell CS vs. NS comp
both studies (columns, see color key) and rescaled by the respective CS vs. NS value. “*” denotes
for the backbone nodes of the neutrophil chemotaxis network (see panel G for details).apolipoprotein A1 (APOA1),α-2-HS glycoprotein (ASHG), and albumin
(ALB) were shared. In addition, down-regulation of APOA1, ALB, and
transferrin also has been reported for lung biopsies of smokers [89].
Moreover, even for the proteins that did not reach signiﬁcance in our
study, the trends were similar to those reported by Nicholas et al. [23]
(Supplementary Fig. 8); for example, for lipocalin-1 (LCN1), a down-
regulation trend was observed in COPD subjects in our study (p-value
(COPD vs. CS) = 0.08, p-value (COPD vs. NS) = 0.07). Of note, beta-
microseminoprotein (MSMB, also known as PSP94) was identiﬁed as
an up-regulated protein in all three previous studies [23,25,88], which
may reﬂect mainly the current smoking status rather than the disease
status. Previously, MSMB was suggested as a candidate biomarker for
increased glandular activity and secretory/goblet cell hyperplasia in
any type of airways disease [23,90].
In total, at least six of the 13differentially abundant proteins in COPD
vs. CS have been linked previously to COPD (Table 2). Of these proteins,
the tissue inhibitor of matrix-metalloproteinases (TIMP1) showed the
strongest correlationwith lung function parameters (Fig. 5B). For exam-
ple, Ziora et al. and Aaron et al. have reported elevated TIMP1 levels in
COPD subjects compared with asymptomatic smokers [69,70]. BPIFB1
(LPLUNC1) is another example protein that was elevated in the COPD
group. BPIFB1 family members have been found in airway submucosal
glands and in a population of airway goblet cells [93], and a strong asso-
ciation between increased BPIFB1 expression and idiopathic pulmonary
ﬁbrosis has been reported [94,95]. Strikingly, overlapping localization
was observed for BPIFB1 andMUC5B likely extending to “bronchiolized
epithelium” of a COPD patient [94], which further supports its potential
role in COPD. C6orf58 is an example for a protein without prior link to
COPD, but little information about C6orf58 is available [91,92].
From a computational methodological point-of-view, it is worth
noting several features of the NPA approach that we used to analyze
the transcriptomics data [45,46]. First, it was applied to cell type-
speciﬁc inﬂammatory network models such as macrophage activa-
tion and neutrophil chemotaxis[47], even though the cellular sputum
RNA contained the mixed contributions from various cell types
(mostly macrophages and neutrophils). We justiﬁed the step by
comparing our results to several public datasets containing isolated
alveolar macrophages, which displayed signiﬁcant similarities and
suggested in particular that the CS vs. NS and FS vs. NS pairwise com-
parisons could be understood in terms of macrophage-related
processes, such as their different polarization states. The NPA ap-
proach also displayed high sensitivity in the case of the COPD vs. CS
and FS vs. NS pairwise comparisons, where it enabled the detection
of perturbed mechanisms even in the absence of differentially
expressed genes (i.e., with adjusted p-values b0.05). For example,
for the activity of the IFNG node, which was found to reverse its
sign upon smoking cessation, the NPA results were conﬁrmed by
the more common GSEA approach (Supplementary Fig. 6), which
provided further conﬁdence in our systems biology-based approach.
Taken together, we and others found that induced sputum can pro-
vide a relevant window into the responsive changes of the airways toold-change heatmap for the 13 differentially expressed proteins between the COPD and CS
ndance (Benjamini–Hochberg adjusted p-value b0.05). (B) Correlation plotswith FEV1% of
teins in COPD vs. CS. The bars show the Pearson correlation coefﬁcient and the red lines the
s across all groups comparedwith the never smoker group (NS) for the differentially abun-
roteins are in blue, themedian of theup- and down-regulated group is indicatedby a black
putumproteins. Proteinswith signiﬁcant differential abundance for CS vs. NS are indicated
ﬁdence interval are given (dashed, red line; gray conﬁdence range). (E) Fold-change com-
er details are similar to (D). (F) Median relative mRNA expression values across all groups
OPD vs. CS comparison for three gene groups, M1-related genes, M2-related genes (see
ar to (C). (G) Network perturbation amplitude (NPA) scatter plot based on transcriptomics
and themacrophage activation networks. The error bars indicate the 95% conﬁdence range
pt and slope of the linear regression model (including the 95% conﬁdence range) are indi-
d the study on alveolar macrophages by Shaykhiev et al. (GSE13896) [60]. Nodes from the
arison are shown (rows). The NPA for these nodes is compared across the study groups for
signiﬁcance; p-value b0.05. (I) NPA scatter plot comparisons for CS vs. NS and COPD vs. NS
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Table 2
Differentially abundant proteins between early-stage COPD subjects and asymptomatic current smokers.
UniProtKB accession Gene symbol Description Log2 FC FDR Literature
P08727 KRT19 Keratin, type I cytoskeletal 19 0.38 0.025 ↑ BALF, PF [98]
↑ BALF, PF [99]
Q6P5S2 C6orf58 UPF0762 protein C6orf58 0.37 0.031
Q5H9A7 TIMP1 Metalloproteinase inhibitor 1 0.29 0.016 ↑ IS, COPD[69]
↑ IS, COPD[70]
Q8TDL5 BPIFB1 [LPLUNC1] BPI fold-containing family B member 1 0.28 0.028 ↑ LB, CF [100]
↑ LP, COPD [101]
P23284 PPIB Peptidyl-prolyl cis-trans isomerase B (cyclophilin B) 0.21 0.016 ↑ NL, Asthma [102]
P02787 TF Serotransferrin −0.23 0.016 ↓ BALF, COPD [103]
↑ IS, COPD[25]
P02765 AHSG Alpha-2-HS-glycoprotein −0.24 0.025 ↓ IS, COPD[23]
P01008 SERPINC1 Antithrombin-III −0.27 0.021
P43652 AFM Afamin −0.32 0.018
P02768 ALB Serum albumin −0.32 0.007 ↓ IS, COPD[23]
↓ IS, COPD[71]
P04196 HRG Histidine-rich glycoprotein −0.36 0.016
P02647 APOA1 Apolipoprotein A-I −0.39 0.016 ↓ IS, COPD [23]
Q96KN2 CNDP1 Beta-Ala-His dipeptidase −0.42 0.016
FC, fold-change [COPDvs. CS] inour study; FDR, false discovery rate (FDR)-adjustedp-value; IS, induced sputum; BALF, bronchio-alveolar lavage;NL, nasal lavage; LP, lungparenchyma; PF,
pulmonary ﬁbrosis; ↑↓= up-/down-regulated; bold, ﬁndings for sputum of COPD subjects.
318 B. Titz et al. / Journal of Proteomics 128 (2015) 306–320toxicant exposures and potentially lung diseases [21,96]. However, it
should be noted that sputum represents a challenging sample type, in
part because of the abundance of highly glycosylated proteins and var-
iations in sample dilution. Because of these dilution effects, it is now rec-
ognized that data normalization is especially critical for sputum
samples. For example, shifts in cell type distributions rather than abso-
lute cell numbers have been found to be more relevant [55]. Similarly,
normalization based on the total protein content was used in our and
previous sputum proteomics studies, and a recent validation study for
COPD biomarkers provided examples that are useful for this type of nor-
malization [71].
While induced sputum clearly captures the responsive changes of
the airways to toxicant exposure, the question is to which extent dis-
ease speciﬁc alterations can be assessed. In our study, the detected
changes in the sputum of COPD subjects generally represented an
ampliﬁcation of the trends already observed in the CS controls,
which is in line with the ﬁndings of previous proteomic studies [23,
25]. Similarly, Gao et al. [97] discussed the challenges associated
with distinguishing COPD subjects from asymptomatic smokersFig. 6. Schematic representation of a basic toxicant-exposure-to-disease-transition model for C
smoker, COPD) and their dominant transitions for smoking-caused COPD. Cigarette smoke exp
These effects often appear ampliﬁed and become irreversible in COPD with a not necessarily s
posure over time and affected bydisease susceptibility of the individual (X-axis) (see text). Smo
transition from a current smoker to COPD. See Sections 1 and 4 for more details.compared with distinguishing asymptomatic or diseased smokers
from non-smoker controls. Therefore, it will be pertinent to explore
other sampling sources, especially to capture the earliest signs of dis-
ease onset. For example, it has been suggested recently that the ear-
liest lesions in COPD are driven by airway epithelial basal progenitor
cells [64], which could encourage the development of more speciﬁc
assays for targeting COPD changes in populations of this cell type.
In conclusion, the present study was designed to assess how biolog-
ical changes are reﬂected in sputum samples over the whole course of
the “toxicant-exposure-to-disease-transition model” for COPD (Fig. 6).
We found that the sputum proteome and transcriptome both captured
the mostly reversible biological responses of the airways to cigarette
smoke exposure including the oxidative/xenobiotic stress response,
changes in mucus production, and protease balance, and alterations in
the state of the respiratory immune system (Fig. 3). The transition
from a still physiological toxicant exposure response to early-stage
COPD disease leaves its marks in the sputum proteome, but the changes
are not strong and mostly an augmentation of the already established
exposure effects. While a few promising targets for COPD detectionOPD. This model represents the four main states (never smokers, current smoker, former
osure induces several effects (Y-axis), of which a subset is detectable in sputum samples.
trict healthy-disease boundary. Overall, disease development is facilitated by cigarette ex-
king cessation is the best establishedmeasure to reduce exposure effects and to prevent the
319B. Titz et al. / Journal of Proteomics 128 (2015) 306–320have been identiﬁed, the identiﬁcation of more speciﬁc signs of early
disease likely will require the discovery of novel mechanistic targets,
potentially those linked to early alterations in basal progenitor cells.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jprot.2015.08.009.
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